Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)
25.13
+0.13
(+0.52%)
Streaming Delayed Price
Updated: 10:10 AM EDT, Aug 27, 2026
Add to My Watchlist
Price and Volume
Detailed Quote| Volume | 19,276 |
| Open | 25.03 |
| Bid (Size) | 24.97 (200) |
| Ask (Size) | 25.29 (100) |
| Prev. Close | 25.00 |
| Today's Range | 24.35 - 25.29 |
| 52wk Range | 5.550 - 29.27 |
| Shares Outstanding | 25,676,798 |
| Dividend Yield | N/A |
Top News
More News
Performance
More News
Read More
Here are the top movers in Tuesday's session. ↗
June 30, 2026
Tuesday's pre-market session: top gainers and losers ↗
June 30, 2026
Here are the top movers in Wednesday's session. ↗
June 24, 2026
Nuvectis (NVCT) Q2 Loss Widens 43% ↗
August 05, 2025
Frequently Asked Questions
Is Nuvectis Pharma, Inc. - Common Stock publicly traded?
Yes, Nuvectis Pharma, Inc. - Common Stock is publicly traded.
What exchange does Nuvectis Pharma, Inc. - Common Stock trade on?
Nuvectis Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nuvectis Pharma, Inc. - Common Stock?
The ticker symbol for Nuvectis Pharma, Inc. - Common Stock is NVCT on the Nasdaq Stock Market
What is the current price of Nuvectis Pharma, Inc. - Common Stock?
The current price of Nuvectis Pharma, Inc. - Common Stock is 25.13
When was Nuvectis Pharma, Inc. - Common Stock last traded?
The last trade of Nuvectis Pharma, Inc. - Common Stock was at 08/27/26 10:10 AM ET
What is the market capitalization of Nuvectis Pharma, Inc. - Common Stock?
The market capitalization of Nuvectis Pharma, Inc. - Common Stock is 645.26M
How many shares of Nuvectis Pharma, Inc. - Common Stock are outstanding?
Nuvectis Pharma, Inc. - Common Stock has 645M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
Facebook
Twitter
YouTube